कंपनी का अवलोकन
GT Biopharma, Inc. operates as a clinical stage biopharmaceutical entity dedicated to the development and commercialization of immuno-oncology products. The company leverages its proprietary Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms to advance therapies such as GTB-3650, which is currently in phase 1 clinical trials. This organization functions within the broader healthcare sector, specifically classified under the biotechnology industry, where innovation in drug discovery and therapeutic delivery mechanisms is paramount. The company's current scale is reflected in a market capitalization of $12.32M, while its annual revenue and employee count are listed as N/A and 1 respectively. These valuation metrics indicate that GT Biopharma is a micro-cap entity with minimal operational footprint, suggesting that its value is derived almost entirely from its intellectual property pipeline and potential future commercialization capabilities rather than existing cash flows or workforce size.
वित्तीय स्वास्थ्य
The financial statements for the trailing twelve months show revenue of N/A, a net income of $-34,449,000, and an EBITDA of N/A. The substantial gap between the non-existent revenue and the significant negative net income reveals a cost structure dominated by research and development expenses typical of clinical-stage biotechnology firms, where the primary expenditure is on advancing assets like GTB-3650 through clinical phases. The company reports free cash flow of $-12,008,125, which indicates a consumption of cash reserves to fund operations and clinical trials, thereby limiting immediate financial flexibility until product approval or commercial milestones are reached. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, a figure that signifies the company has not yet generated commercial sales to realize any profitability on its cost of goods sold or operating expenses. Regarding liquidity, the company holds $6.81M in cash against $0 in debt, resulting in a debt-to-equity ratio of N/A due to the absence of debt obligations. This balance sheet structure is conservative in terms of leverage but constrained by the need to burn cash rapidly for survival. The current ratio stands at 3.50, which indicates a strong short-term liquidity position where current assets significantly exceed current liabilities, providing a buffer against immediate financial obligations. However, the return on equity is -1377.4% and the return on assets is -125.9%, revealing that management effectiveness in generating returns from shareholder capital and assets is currently negative due to the pre-revenue stage of the business model.
मूल्यांकन आकलन
The trailing P/E ratio is N/A, while the forward P/E is listed as -0.04, a disparity that implies the market expects the company to achieve profitability in the future, although the negative forward P/E currently reflects the lack of near-term earnings power. The price-to-book ratio is 1.72, indicating that the market values the company at a premium of 72% over its net book value, which often suggests confidence in the intangible value of its clinical pipeline despite the lack of current earnings. The price-to-sales ratio and EV/EBITDA are both N/A, suggesting that traditional sales-based or earnings-based valuation multiples are not applicable to a firm with no reported revenue or EBITDA. In terms of trading range, the stock has a 52-week high of $3.85 and a 52-week low of $0.38, meaning the current price sits at a point where the volatility has been extreme over the past year. The beta value is 1.20, which means the stock price is expected to be 20% more volatile than the broader market, reflecting the high risk associated with clinical-stage biotechnology investments where outcomes are binary and uncertain.
Growth & Income
The revenue growth year-over-year and earnings growth year-over-year are both N/A, as the company has not yet generated sufficient revenue to calculate these growth metrics. Since the company is in the clinical stage with no commercial sales, the concept of earnings growing faster or slower than revenue is not applicable, as the primary focus remains on capitalizing the pipeline rather than expanding revenue streams. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%. Consequently, the company reinvests all available resources, including its $6.81M cash balance, into research and development activities rather than distributing income to shareholders. The overall growth and income profile is characterized by a complete absence of current income generation, with all financial activity directed toward the high-risk, high-reward endeavor of developing immuno-oncology products for commercialization.